Also found in: Medical.
CDK6Cyclin Dependent Kinase 6
References in periodicals archive ?
Percentage of BrdU positive cells as well as expression levels of cyclinD1, CDK6, CDK4, and VEGF was significantly reduced by either LY294002 or SP600125 relative to the LIPUS group (P<0.05 or P< 0.01, Figure 5A and B).
As a result, it was established that the disease can be therapeutically targeted by repurposing palbociclib as the drug drives malignant CDK6 cells into death.
Scientists at Newcastle University performed genomic analysis on AML cells and identified that the key molecules involved in the progression of leukaemia are CDK6 and CCND2.
RT-PCR analysis in the present study demonstrated that ISO-treated HT-29 cells significantly decreased CCNDI and CDK6 expressions with respect to the control group cells (p<0.05).
CDK6 associates with centrosome during mitosis and is mutated in large Pakistani family with primary microcephaly.
Przyborski et al., "A role for NANOG in G1 to S transition in human embryonic stem cells through direct binding of CDK6 and CDC25A," The Journal of Cell Biology, vol.
Rugo et al., "MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, n patients with refractory HR+/HER2- metastatic breast cancer," Clinical Cancer Research, vol.
The downregulation of let-7 upregulates some cell cycle regulators such as cyclin A2, cyclin D1/2, CDK6, CDC34, CDC25A, Aurora A and B kinases, CDK8, PLAGL2, and TRIM71, which results in the activation of cell cycle [11, 42].
The main molecular targets for gga-miR-302b-3p were MAP3K14, E2F7, LATS2, TRPS1, CDK6, RAPGEF2, and TGFfiR2.
Bcl2, Ccnd1, Cdk6, and Sox4), intestinal stem cells (Lgr5, Olfm4, and Bmi1) [10], mucin biology (Muc2 and Muc6), and tight junctions (occludin, zonulin-1, and Jam) was analyzed using real-time PCR (Table S1).
CDK4 and CDK6 associate with cyclin D and participate in G1 phase progression.
Eli Lilly and Co.'s Phase III JUNIPER study evaluating Verzenio (abemaciclib), a cyclin-dependent kinase (CDK)4 and CDK6 inhibitor, as monotherapy in KRAS-mutated, advanced non-small lung cancer (NSCLC) did not meet its primary endpoint of overall survival (OS).